|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.34 USD | +0.05% |
|
-1.03% | +6.19% |
| 07-22 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 07-21 | Gilead Sciences Shares Fall After Downgrade From Leerink Partners | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 162B | - | ||||
| 1,037B | |||||
| 615B | |||||
| 448B | |||||
| 326B | |||||
| 293B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
